



Biocon: Company Statement on Media Reports on USFDA 483s

Bengaluru, Karnataka, India, May 10, 2017:

“With reference to Media Reports on USFDA 483s for Biocon, observations on form 483 is a standard outcome of any audit. Biocon has already responded to USFDA on all observations of the recent audit within stipulated timelines.

As a policy we do not comment on any schedule or outcomes of regulatory inspections, unless we believe that there is a material impact. Biocon has a good track record of inspections by the USFDA, European regulators and other regulators from developed and emerging markets.”

- Company Spokesperson

For further information or query, please reach out to:

Seema Ahuja	Rumman Ahmed
VP & Global Head of Communications	Sr. Manager-Corporate Communications
Biocon Limited	Biocon Limited
T: +91-80-2808-2222, M:+91-9972317792	T: +91 80 28082223, M:+91-9845104173
Email: seema.ahuja@biocon.com	Email: rumman.ahmed@biocon.com